CAMBRIDGE, MA., – October 23, 2023 – HiFiBiO Therapeutics Founder, Chairperson, and CEO Liang Schweizer presents, in the peer-reviewed journal Drug Discovery Today, the company’s proprietary translational platform Drug Intelligence Science (DIS®), highlighting its potential to overcome industry challenges and redefine drug development. Leveraging DIS®, HiFiBiO Therapeutics has accelerated a pipeline of immune-oncology (IO) and autoimmune antibody programs including three novel IO therapeutics (TNFR2 agonist, OX40 agonist, BTLA antagonist) currently in Phase 1 clinical trials for the treatment of DIS® selected advanced solid tumors.
Liang Schweizer, PhD, remarked, “Regrettably, many innovative therapeutics fail to navigate the complex drug discovery and development process due to lack of effective translation from preclinical research to clinical application. Our unique DIS® platform addresses major industry roadblocks, such as irrelevant targets, low lead quality, and limited clinical translatability. It does so by offering an innovative approach that combines cutting-edge AI/ML capabilities with single cell science to enhance the probability of success from target identification to patient benefit. I hope this novel approach will lead to an industry paradigm shift for effective drug discovery and development.”
The DIS® platform empowers the translation of single cell insights from patient samples into more relevant drug targets, superior antibody candidates, and informed trial-related decisions, including indications, biomarkers, and patient selection. In addition to advancing its own pipeline, HiFiBiO Therapeutics has partnered with numerous academic institutions and pharmaceutical companies to further validate and broaden DIS® platform applications.
Abstract of the Publication
Translational research plays a critical role in bridging the gap between basic biology discoveries and their clinical applications. Deep scientific understanding and advanced technology platforms are both critical for translational research. This paper describes a novel integrated Drug Intelligence Science (DIS®) translational platform that combines single cell technology with artificial intelligence (AI) and machine learning (ML) to gain insights for high resolution cell biology, thus enabling the discovery of disease relevant targets, high-quality drug candidates, and predictive biomarkers. The innovative DIS® approach has the potential to provide an unprecedented mechanistic understanding of human disease and to enable in-depth pharmacological profiling of drug candidates to increase the probability of success in drug discovery and development.
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is a global clinical stage biotech pioneering a unique high-resolution translational platform (DIS®, Drug Intelligence Science) to enhance the probability of success for immunotherapies. DIS® combines unique single cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers. With DIS®, HiFiBiO gains an unprecedented understanding of immune modulation in human diseases which drives a robust clinical pipeline of transformative immunotherapies. Additionally, HiFiBiO has partnered with major multinational pharmaceutical and biotech companies applying its innovative DIS® platform and it has been recognized as one of 2023’s Fierce 15 biotech companies. Additional information can be found at www.Hifibio.com.
HiFiBiO® and DIS® are trademarks of HiFiBiO Therapeutics and its affiliates.